Aristopin5 ml

Atropine sulfate is an injectable anticholinergic medicine used across several distinct emergency and clinical situations:

Cardiac Emergencies

• Symptomatic bradycardia to increase a dangerously slow heart rate, including in the setting of acute myocardial infarction with vagally mediated bradycardia
• Certain AV nodal conduction blocks with hemodynamic instability

Poisoning and Toxicology

• Organophosphate and carbamate (nerve agent/pesticide) poisoning a critical, life-saving antidote that blocks the excessive muscarinic (cholinergic) effects caused by these poisons
• Certain mushroom poisonings (muscarine-containing species), under toxicology guidance

Perioperative and Procedural Use

• Preoperative medication to reduce salivary and bronchial secretions and to counteract vagal reflexes (such as bradycardia) during anaesthesia and surgery
• Reversal of neuromuscular blockade given with an anticholinesterase agent (such as neostigmine) to counteract the excessive muscarinic side effects (such as bradycardia and secretions) of the reversal agent

Diagnostic and Other Uses

• Antispasmodic use in certain gastrointestinal and genitourinary conditions involving smooth muscle spasm, in some clinical settings

Atropine sulfate is also used, as a separate ophthalmic formulation, for pupil dilation and treatment of certain eye conditions; this entry covers the injectable formulation.

Contains Aristopin 5 ml for intravenous, intramuscular, or subcutaneous injection, commonly supplied as ampoules or pre-filled auto-injectors in various strengths (such as 0.6 mg/mL or 1 mg/mL, and higher-concentration auto-injectors for emergency nerve agent/organophosphate use). Exact strengths and presentations vary by product and intended emergency use; confirm the specific concentration on the product dispensed.

Atropine sulfate is an injectable anticholinergic medicine with several distinct emergency and clinical uses: it speeds up a dangerously slow heart rate, serves as the essential antidote for organophosphate and nerve agent poisoning, reduces secretions before surgery, and helps reverse certain effects of other medicines used in anaesthesia. It works by blocking the action of acetylcholine, a nerve chemical that, among other things, slows the heart rate and stimulates glandular secretions - by blocking this effect, atropine speeds the heart and dries secretions.

Therapeutic Class: Anticholinergic (Antimuscarinic) Agent

After intravenous injection, atropine acts within a few minutes, with effects on heart rate and secretions occurring rapidly; after intramuscular injection, onset is somewhat slower. It is widely distributed throughout the body, including across the blood-brain barrier, which accounts for some of its central nervous system effects at higher doses. Atropine is metabolized partly in the liver and excreted mainly by the kidneys, with an elimination half-life of approximately 2-3 hours in healthy adults, though clinical effects at the doses used for emergencies (such as organophosphate poisoning) are governed more by repeat dosing to effect than by a fixed half-life-based schedule.

• Administered by intravenous, intramuscular, or subcutaneous injection, by a trained healthcare professional
• The intravenous route is preferred in emergencies (bradycardia, poisoning) for the fastest onset of effect
• In mass-casualty or field settings (such as nerve agent exposure), pre-filled auto-injectors are used for rapid intramuscular self- or buddy-administration, following specific training and protocols
• In organophosphate poisoning, atropine is titrated to clinical endpoints (clearing of secretions, improved heart rate and breathing) rather than to a fixed total dose

The following should be assessed by the treating clinical team before or during atropine administration:

• Other anticholinergic medicines (such as certain antihistamines, tricyclic antidepressants, and antipsychotics): additive anticholinergic effects can increase the risk of confusion, urinary retention, and other antimuscarinic side effects.
• Cholinesterase inhibitors (such as neostigmine, physostigmine, or organophosphate/nerve agent exposure itself): atropine specifically counteracts the muscarinic effects of these agents; dosing in these contexts is deliberately interactive and managed by the treating clinician.
• Drugs affecting heart rate (such as beta-blockers or digoxin): atropine's heart-rate-increasing effect may be altered by concurrent use of these medicines; the clinical team monitors heart rate and rhythm closely.
• Antacids: may affect absorption if atropine were given orally in some formulations, though this is less relevant to the injectable form used in emergencies.

Common side effects (dose-related)

• Dry mouth
• Blurred vision and pupil dilation
• Flushed, dry skin
• Tachycardia (fast heart rate)
• Urinary retention or hesitancy
• Reduced sweating

Serious side effects (seek urgent medical attention)

• Central anticholinergic syndrome: confusion, agitation, hallucinations, and, in severe cases, coma, particularly with higher doses or in elderly or susceptible patients.
• Significant tachycardia or cardiac arrhythmia, particularly in patients with underlying heart disease.
• Hyperthermia, particularly in warm environments or in children, due to reduced sweating.
• Signs of urinary retention: inability to urinate, lower abdominal discomfort.
• Signs of a severe allergic reaction: rash, swelling, difficulty breathing.

Pregnancy

Atropine crosses the placenta. In genuine emergencies (such as organophosphate poisoning or maternal bradycardia), it is used in pregnancy when clinically necessary, since the risk of untreated poisoning or bradycardia to both mother and fetus outweighs the risks of treatment; for elective or non-emergency use, the treating physician weighs benefits against risks.

Breastfeeding

Atropine is excreted in breast milk in small amounts; use during breastfeeding for emergency indications should not be delayed, and non-emergency use should be discussed with a healthcare professional.

• Heat intolerance: atropine reduces sweating, which can predispose to heatstroke, particularly in children, in hot environments, or with physical exertion during treatment.
• Elderly patients: more susceptible to central anticholinergic effects (confusion, agitation) and urinary retention; use with caution.
• Cardiac monitoring: in bradycardia treatment, monitor for excessive tachycardia or new arrhythmia as the dose is titrated.
• Organophosphate poisoning: atropine treats only the muscarinic effects of poisoning; a second agent (such as pralidoxime) is generally needed to address the nicotinic effects (muscle weakness, paralysis) and to reactivate the inhibited enzyme; atropine alone does not fully treat severe organophosphate poisoning.
• In hot climates, patients receiving atropine (or those exposed to atropine-containing auto-injectors in a mass-casualty response) should be monitored for hyperthermia.

Atropine overdose produces an exaggerated anticholinergic (antimuscarinic) toxidrome, classically remembered as "hot as a hare, blind as a bat, dry as a bone, red as a beet, and mad as a hatter" - referring to hyperthermia, blurred vision/dilated pupils, dry mouth and skin, flushed skin, and confusion or delirium. Severe overdose can progress to significant tachycardia, cardiac arrhythmia, agitation, hallucinations, seizures, and coma. Suspected significant atropine overdose is a medical emergency requiring immediate treatment. Management includes supportive care (cooling for hyperthermia, benzodiazepines such as diazepam for agitation or seizures - avoiding excessive sedation that could cause respiratory depression), and, for severe delirium or coma, the specific antidote physostigmine, a cholinesterase inhibitor that reverses both central and peripheral anticholinergic effects; physostigmine is given cautiously, slowly, with cardiac monitoring, due to its own risk of inducing excessive cholinergic effects (bradycardia, seizures) if given too rapidly or in excess.

Store ampoules and pre-filled injectors at controlled room temperature, protected from light, as directed on the product label. Do not freeze. Auto-injector devices used for emergency/field use have specific storage and expiry requirements per the manufacturer, given their role in time-critical poisoning response.

• Children: Used for bradycardia, organophosphate poisoning, and preoperative indications, with weight-based dosing determined by the treating physician; children are more susceptible to heat-related complications due to reduced sweating.
• Elderly: More susceptible to central anticholinergic effects and urinary retention; use with caution, particularly outside emergency indications.
• Down syndrome: Some patients with Down syndrome show increased sensitivity to atropine's cardiac and pupillary effects; use with caution and close monitoring if this population requires atropine.

Duration and repeat dosing depend entirely on the indication: bradycardia treatment is typically a single dose or a few repeated doses until heart rate improves; organophosphate poisoning treatment continues, with repeated dosing, until the patient is adequately "atropinized" and secretions and bronchospasm are controlled, which may take hours in severe poisoning; preoperative use is a single dose given shortly before the procedure.

Drug Class: Belladonna alkaloid; muscarinic acetylcholine receptor antagonist

Atropine works as a competitive antagonist at muscarinic acetylcholine receptors throughout the body, blocking the effects of acetylcholine at these sites. This action increases heart rate (by blocking the vagus nerve's slowing effect on the heart), reduces salivary, bronchial, and other secretions, relaxes smooth muscle, and dilates the pupils. In organophosphate poisoning, atropine specifically counteracts the excessive muscarinic stimulation (excessive secretions, bradycardia, bronchospasm) caused by the poison's inhibition of acetylcholinesterase, without reversing the poison's separate nicotinic effects (such as muscle weakness), for which additional treatment (such as pralidoxime) is needed.

Atropine sulfate is used in children for bradycardia, organophosphate poisoning, and preoperative indications, with weight-based dosing determined by the treating physician. Children are more susceptible to atropine-related hyperthermia due to reduced sweating, so temperature should be monitored closely, particularly in warm environments.